These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 2695487

  • 1. [What is assured in therapy with HMG-CoA reductase inhibitors (cholesterol synthesis inhibitors)?].
    Knisel W, Eggstein M.
    Internist (Berl); 1989 Dec; 30(12):776-83. PubMed ID: 2695487
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Hydroxymethylglutaryl coenzyme A reductase inhibitors].
    Schuff-Werner P.
    Internist (Berl); 1994 Mar; 35(3):288-94; discussion 295. PubMed ID: 8175295
    [No Abstract] [Full Text] [Related]

  • 4. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
    Branchi A, Rovellini A, Fiorenza AM, Sommariva D.
    Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
    [Abstract] [Full Text] [Related]

  • 5. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J, Yamamoto K, Kobori S, Setoguchi Y, Sato Y, Matsunaga A, Shichiri M, Sakai T, Kono S, Arakawa K.
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [Abstract] [Full Text] [Related]

  • 6. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE, Phillips JO, Mohiuddin SM, Ryschon KL, Pedersen CA.
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
    da Silva VB, Taft CA, Silva CH.
    J Phys Chem A; 2008 Mar 13; 112(10):2007-11. PubMed ID: 18044855
    [Abstract] [Full Text] [Related]

  • 11. Lipid disturbances in chronic renal failure--patomechanisms and treatment.
    Rutkowski B, Chmielewski M.
    Rocz Akad Med Bialymst; 2004 Mar 13; 49():139-44. PubMed ID: 15631330
    [Abstract] [Full Text] [Related]

  • 12. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR, Pula KK, Alton KB, Burrier RE, Watkins RW.
    Metabolism; 2001 Oct 13; 50(10):1234-41. PubMed ID: 11586500
    [Abstract] [Full Text] [Related]

  • 13. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
    Motz W.
    MMW Fortschr Med; 2003 Oct 09; 145(41):48. PubMed ID: 14655487
    [No Abstract] [Full Text] [Related]

  • 14. Choice of lipid-regulating drugs.
    Med Lett Drugs Ther; 2001 May 28; 43(1105):43-8. PubMed ID: 11378632
    [No Abstract] [Full Text] [Related]

  • 15. Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.
    Pfefferkorn JA, Choi C, Song Y, Trivedi BK, Larsen SD, Askew V, Dillon L, Hanselman JC, Lin Z, Lu G, Robertson A, Sekerke C, Auerbach B, Pavlovsky A, Harris MS, Bainbridge G, Caspers N.
    Bioorg Med Chem Lett; 2007 Aug 15; 17(16):4531-7. PubMed ID: 17574411
    [Abstract] [Full Text] [Related]

  • 16. Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients.
    Lal SM, Katyal A.
    Mo Med; 2002 Aug 15; 99(10):580-4. PubMed ID: 12534147
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combination therapy with HMG CoA reductase inhibitors and gemfibrozil: practical or perilous?
    Duell PB, Illingworth DR.
    Heart Dis Stroke; 1993 Aug 15; 2(3):260-2. PubMed ID: 8137035
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.